Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Alisertib for Acute Myeloid Leukemia
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01779843
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
- Conditions
- Myelogenous Leukemia, Acute
- Interventions
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT01773408
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Cancer Therapy & Research Ctr; Dept Institute for Drug Development, San Antonio, Texas, United States
🇨🇦McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-01-28
- Target Recruit Count
- 48
- Registration Number
- NCT01700413
- Locations
- 🇪🇸
Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Spain
🇪🇸Hospital Clinic I Provincial de Barcelona, Barcelona, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT01692197
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Refractory Anemia With Excess BlastsAdult Acute Myelomonocytic Leukemia (M4)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01607645
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT01518556
- Locations
- 🇰🇷
Division of Hematology-Oncology, Konkuk University Medical Center, Seoul, Korea, Republic of
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: microtransplantationDrug: idarubicin
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT01484171
- Locations
- 🇨🇳
The Affiliated Hospital of the Chinese Academy of Military Medical Science, Beijing, Beijing, China
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
- Conditions
- Acute Myeloblastic Leukemia
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 55
- Registration Number
- NCT01435343
- Locations
- 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
- Conditions
- Acute Myeloblastic Leukemia
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT01296178
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 282
- Registration Number
- NCT01289457
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.